Insulin Centennial : Milestones influencing the development of insulin preparations since 1922
© 2021 John Wiley & Sons Ltd..
During 1921 to 1922, a team effort by Banting, Macleod, Collip and Best isolated and purified insulin and demonstrated its life-giving properties, giving rise to the birth of insulin therapy. In the early years (1922-1950), priorities revolved around the manufacture of insulin to meet demand, improving purity to avoid allergic reactions, establishing insulin standards and increasing its duration of action to avoid multiple daily injections. Shortly after the emergence of insulin, Joslin and Allen advocated the need to achieve and maintain good glycaemic control to realize its full potential. Although this view was opposed by some during a dark period in the history of insulin, it was subsequently endorsed some 60 years later endorsed by the Diabetes Control and Complications Trial and United Kingdom Prospective Diabetes Study. Major scientific advances by the Nobel Laureates Sanger, Hodgkin, Yalow and Gilbert and also by Steiner have revolutionized the understanding of diabetes and facilitated major advances in insulin therapy. The more recent advent of recombinant technology over the last 40 years has provided the potential for unlimited source of insulin, and the ability to generate various insulin 'analogues', in an attempt to better replicate normal insulin secretory patterns. The emerging biosimilars now provide the opportunity to improve availability at a lower cost.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:24 Suppl 1 |
---|---|
Enthalten in: |
Diabetes, obesity & metabolism - 24 Suppl 1(2022) vom: 01. Jan., Seite 27-42 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Owens, David R [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 31.03.2022 Date Revised 31.05.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1111/dom.14587 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM332472582 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM332472582 | ||
003 | DE-627 | ||
005 | 20231225215638.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1111/dom.14587 |2 doi | |
028 | 5 | 2 | |a pubmed24n1108.xml |
035 | |a (DE-627)NLM332472582 | ||
035 | |a (NLM)34708913 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Owens, David R |e verfasserin |4 aut | |
245 | 1 | 0 | |a Insulin Centennial |b Milestones influencing the development of insulin preparations since 1922 |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 31.03.2022 | ||
500 | |a Date Revised 31.05.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2021 John Wiley & Sons Ltd. | ||
520 | |a During 1921 to 1922, a team effort by Banting, Macleod, Collip and Best isolated and purified insulin and demonstrated its life-giving properties, giving rise to the birth of insulin therapy. In the early years (1922-1950), priorities revolved around the manufacture of insulin to meet demand, improving purity to avoid allergic reactions, establishing insulin standards and increasing its duration of action to avoid multiple daily injections. Shortly after the emergence of insulin, Joslin and Allen advocated the need to achieve and maintain good glycaemic control to realize its full potential. Although this view was opposed by some during a dark period in the history of insulin, it was subsequently endorsed some 60 years later endorsed by the Diabetes Control and Complications Trial and United Kingdom Prospective Diabetes Study. Major scientific advances by the Nobel Laureates Sanger, Hodgkin, Yalow and Gilbert and also by Steiner have revolutionized the understanding of diabetes and facilitated major advances in insulin therapy. The more recent advent of recombinant technology over the last 40 years has provided the potential for unlimited source of insulin, and the ability to generate various insulin 'analogues', in an attempt to better replicate normal insulin secretory patterns. The emerging biosimilars now provide the opportunity to improve availability at a lower cost | ||
650 | 4 | |a Historical Article | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Insulin preparations | |
650 | 4 | |a biosimilar insulin | |
650 | 4 | |a insulin analogues | |
650 | 4 | |a insulin standardisation | |
650 | 4 | |a insulin therapy | |
650 | 7 | |a Biosimilar Pharmaceuticals |2 NLM | |
650 | 7 | |a Hypoglycemic Agents |2 NLM | |
650 | 7 | |a Insulin |2 NLM | |
650 | 7 | |a Insulin, Regular, Human |2 NLM | |
700 | 1 | |a Monnier, Louis |e verfasserin |4 aut | |
700 | 1 | |a Ceriello, Antonio |e verfasserin |4 aut | |
700 | 1 | |a Bolli, Geremia B |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Diabetes, obesity & metabolism |d 1999 |g 24 Suppl 1(2022) vom: 01. Jan., Seite 27-42 |w (DE-627)NLM111220432 |x 1463-1326 |7 nnns |
773 | 1 | 8 | |g volume:24 Suppl 1 |g year:2022 |g day:01 |g month:01 |g pages:27-42 |
856 | 4 | 0 | |u http://dx.doi.org/10.1111/dom.14587 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 24 Suppl 1 |j 2022 |b 01 |c 01 |h 27-42 |